Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Fungemia caused by Aureobasidium pullulans in a patient with advanced AIDS: a case report and review of the medical literature.

Mittal J, Szymczak WA, Pirofski LA, Galen BT.

JMM Case Rep. 2018 Mar 14;5(4):e005144. doi: 10.1099/jmmcr.0.005144. eCollection 2018 Apr.

2.

A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice.

Doyle CR, Moon JY, Daily JP, Wang T, Pirofski LA.

Infect Immun. 2018 Jun 21;86(7). pii: e00300-18. doi: 10.1128/IAI.00300-18. Print 2018 Jul.

PMID:
29735523
3.

A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis.

Casadevall A, Pirofski LA.

Clin Infect Dis. 2018 Jun 1;66(12):1937-1939. doi: 10.1093/cid/ciy188. No abstract available.

PMID:
29697770
4.

Antibody and B Cell Subset Perturbations in Human Immunodeficiency Virus-Uninfected Patients With Cryptococcosis.

Rohatgi S, Nakouzi A, Carreño LJ, Slosar-Cheah M, Kuniholm MH, Wang T, Pappas PG, Pirofski LA.

Open Forum Infect Dis. 2017 Nov 18;5(1):ofx255. doi: 10.1093/ofid/ofx255. eCollection 2018 Jan.

5.
6.

What Is a Host? Attributes of Individual Susceptibility.

Casadevall A, Pirofski LA.

Infect Immun. 2018 Jan 22;86(2). pii: e00636-17. doi: 10.1128/IAI.00636-17. Print 2018 Feb. Review.

PMID:
29084893
7.

Virulence profile: Liise-anne Pirofski.

Pirofski LA.

Virulence. 2018 Jan 1;9(1):275-277. doi: 10.1080/21505594.2017.1382277. Epub 2017 Nov 10. No abstract available.

8.

Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline.

Pirofski LA.

J Infect Dis. 2017 Sep 15;216(suppl_5):S611-S612. doi: 10.1093/infdis/jix270. No abstract available.

PMID:
28938039
9.

Bundle in the Bronx: Impact of a Transition-of-Care Outpatient Parenteral Antibiotic Therapy Bundle on All-Cause 30-Day Hospital Readmissions.

Madaline T, Nori P, Mowrey W, Zukowski E, Gohil S, Sarwar U, Weston G, Urrely R, Palombelli M, Pierino VF, Parsons V, Ehrlich A, Ostrowsky B, Corpuz M, Pirofski LA.

Open Forum Infect Dis. 2017 Jun 29;4(2):ofx097. doi: 10.1093/ofid/ofx097. eCollection 2017 Spring.

10.

Naïve B cells reduce fungal dissemination in Cryptococcus neoformans infected Rag1-/- mice.

Dufaud C, Rivera J, Rohatgi S, Pirofski LA.

Virulence. 2018 Jan 1;9(1):173-184. doi: 10.1080/21505594.2017.1370529. Epub 2017 Oct 4.

11.

Developing Interactive Antimicrobial Stewardship and Infection Prevention Curricula for Diverse Learners: A Tailored Approach.

Nori P, Madaline T, Munjal I, Bhar S, Guo Y, Seo SK, Porrovecchio A, Gancher E, Nosanchuk J, Pirofski LA, Ostrowsky B.

Open Forum Infect Dis. 2017 Jul 20;4(3):ofx117. doi: 10.1093/ofid/ofx117. eCollection 2017 Summer.

12.

Help is on the way: Monoclonal antibody therapy for multi-drug resistant bacteria.

Babb R, Pirofski LA.

Virulence. 2017 Oct 3;8(7):1055-1058. doi: 10.1080/21505594.2017.1306620. Epub 2017 Mar 17. No abstract available.

13.

A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Schumann B, Hahm HS, Parameswarappa SG, Reppe K, Wahlbrink A, Govindan S, Kaplonek P, Pirofski LA, Witzenrath M, Anish C, Pereira CL, Seeberger PH.

Sci Transl Med. 2017 Mar 8;9(380). pii: eaaf5347. doi: 10.1126/scitranslmed.aaf5347.

14.

A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Parameswarappa SG, Reppe K, Geissner A, Ménová P, Govindan S, Calow ADJ, Wahlbrink A, Weishaupt MW, Monnanda BP, Bell RL, Pirofski LA, Suttorp N, Sander LE, Witzenrath M, Pereira CL, Anish C, Seeberger PH.

Cell Chem Biol. 2016 Nov 17;23(11):1407-1416. doi: 10.1016/j.chembiol.2016.09.016. Epub 2016 Nov 3.

15.

Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.

De La Rosa I, Munjal IM, Rodriguez-Barradas M, Yu X, Pirofski LA, Mendoza D.

Clin Vaccine Immunol. 2016 Jun 6;23(6):524-529. doi: 10.1128/CVI.00026-16. Print 2016 Jun.

16.
17.

The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.

Casadevall A, Pirofski LA.

PLoS Pathog. 2015 Apr 23;11(4):e1004717. doi: 10.1371/journal.ppat.1004717. eCollection 2015 Apr. Review. No abstract available.

18.

What is infectiveness and how is it involved in infection and immunity?

Pirofski LA, Casadevall A.

BMC Immunol. 2015 Mar 26;16:13. doi: 10.1186/s12865-015-0076-1. Review.

19.

Host immunity to Cryptococcus neoformans.

Rohatgi S, Pirofski LA.

Future Microbiol. 2015;10(4):565-81. doi: 10.2217/fmb.14.132. Review.

20.

Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.

Rodriguez-Barradas MC, Serpa JA, Munjal I, Mendoza D, Rueda AM, Mushtaq M, Pirofski LA.

J Infect Dis. 2015 Jun 1;211(11):1703-11. doi: 10.1093/infdis/jiu819. Epub 2014 Dec 23.

21.

Microbiology: Ditch the term pathogen.

Casadevall A, Pirofski LA.

Nature. 2014 Dec 11;516(7530):165-6. doi: 10.1038/516165a. No abstract available.

PMID:
25503219
22.

What is a host? Incorporating the microbiota into the damage-response framework.

Casadevall A, Pirofski LA.

Infect Immun. 2015 Jan;83(1):2-7. doi: 10.1128/IAI.02627-14. Epub 2014 Nov 10. Review.

23.

An ahemolytic pneumolysin of Streptococcus pneumoniae manipulates human innate and CD4⁺ T-cell responses and reduces resistance to colonization in mice in a serotype-independent manner.

Khan MN, Coleman JR, Vernatter J, Varshney AK, Dufaud C, Pirofski LA.

J Infect Dis. 2014 Nov 15;210(10):1658-69. doi: 10.1093/infdis/jiu321. Epub 2014 Jun 13.

24.

Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae.

Olaya-Abril A, Prados-Rosales R, McConnell MJ, Martín-Peña R, González-Reyes JA, Jiménez-Munguía I, Gómez-Gascón L, Fernández J, Luque-García JL, García-Lidón C, Estévez H, Pachón J, Obando I, Casadevall A, Pirofski LA, Rodríguez-Ortega MJ.

J Proteomics. 2014 Jun 25;106:46-60. doi: 10.1016/j.jprot.2014.04.023. Epub 2014 Apr 24.

PMID:
24769240
25.

Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.

Rohatgi S, Gohil S, Kuniholm MH, Schultz H, Dufaud C, Armour KL, Badri S, Mailliard RB, Pirofski LA.

MBio. 2013 Aug 27;4(5):e00573-13. doi: 10.1128/mBio.00573-13.

26.

X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.

Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski LA.

MBio. 2013 Jul 2;4(4). pii: e00265-13. doi: 10.1128/mBio.00265-13.

27.

Current concepts in host-microbe interaction leading to pneumococcal pneumonia.

Vernatter J, Pirofski LA.

Curr Opin Infect Dis. 2013 Jun;26(3):277-83. doi: 10.1097/QCO.0b013e3283608419. Review.

28.

Exserohilum rostratum fungal meningitis associated with methylprednisolone injections.

Casadevall A, Pirofski LA.

Future Microbiol. 2013 Feb;8(2):135-7. doi: 10.2217/fmb.12.138. No abstract available.

29.

Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.

Rohatgi S, Pirofski LA.

J Immunol. 2012 Dec 15;189(12):5820-30. doi: 10.4049/jimmunol.1201514. Epub 2012 Nov 21.

30.

Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection.

Hofmeyer KA, Scandiuzzi L, Ghosh K, Pirofski LA, Zang X.

J Immunol. 2012 Sep 15;189(6):3054-63. doi: 10.4049/jimmunol.1200701. Epub 2012 Aug 1.

31.

Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Casadevall A, Pirofski LA.

Cell Host Microbe. 2012 May 17;11(5):447-56. doi: 10.1016/j.chom.2012.04.004. Review.

32.

IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.

Szymczak WA, Sellers RS, Pirofski LA.

Am J Pathol. 2012 Apr;180(4):1547-59. doi: 10.1016/j.ajpath.2011.12.038. Epub 2012 Feb 16.

33.

CD8+ T cells and risk for bacterial pneumonia and all-cause mortality among HIV-infected women.

Gohil SK, Heo M, Schoenbaum EE, Celentano D, Pirofski LA.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):191-8. doi: 10.1097/QAI.0b013e31824d90fe.

34.

Q and A: What is a pathogen? A question that begs the point.

Pirofski LA, Casadevall A.

BMC Biol. 2012 Jan 31;10:6. doi: 10.1186/1741-7007-10-6. No abstract available.

35.
36.

A new synthesis for antibody-mediated immunity.

Casadevall A, Pirofski LA.

Nat Immunol. 2011 Dec 16;13(1):21-8. doi: 10.1038/ni.2184.

37.

Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency?

Marr KA, Datta K, Pirofski LA, Barnes R.

Clin Infect Dis. 2012 Jan 1;54(1):153-4. doi: 10.1093/cid/cir756. Epub 2011 Nov 10. No abstract available.

PMID:
22075791
38.

Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing.

Yano M, Gohil S, Coleman JR, Manix C, Pirofski LA.

MBio. 2011 Nov 1;2(5). pii: e00176-11. doi: 10.1128/mBio.00176-11. Print 2011.

39.

The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response.

Seyoum B, Yano M, Pirofski LA.

Vaccine. 2011 Oct 19;29(45):8002-11. doi: 10.1016/j.vaccine.2011.08.064. Epub 2011 Aug 22.

40.

Microbial virulence as an emergent property: consequences and opportunities.

Casadevall A, Fang FC, Pirofski LA.

PLoS Pathog. 2011 Jul;7(7):e1002136. doi: 10.1371/journal.ppat.1002136. Epub 2011 Jul 21. Review. No abstract available.

41.

Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias.

Coleman JR, Papamichail D, Yano M, García-Suárez Mdel M, Pirofski LA.

J Infect Dis. 2011 May 1;203(9):1264-73. doi: 10.1093/infdis/jir010. Epub 2011 Feb 21.

42.

V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons.

Serpa JA, Valayam J, Musher DM, Rossen RD, Pirofski LA, Rodriguez-Barradas MC.

Clin Vaccine Immunol. 2011 Mar;18(3):362-6. doi: 10.1128/CVI.00408-10. Epub 2011 Jan 12.

43.

CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice.

Weber SE, Tian H, Pirofski LA.

J Immunol. 2011 Jan 1;186(1):432-42. doi: 10.4049/jimmunol.1001963. Epub 2010 Dec 6.

44.

Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8.

Yano M, Pirofski LA.

Clin Vaccine Immunol. 2011 Jan;18(1):59-66. doi: 10.1128/CVI.00368-10. Epub 2010 Nov 10.

45.

The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.

Fabrizio K, Manix C, Tian H, van Rooijen N, Pirofski LA.

Vaccine. 2010 Nov 3;28(47):7542-50. doi: 10.1016/j.vaccine.2010.08.061. Epub 2010 Aug 26.

46.

Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue.

Pirofski LA.

J Clin Invest. 2010 Sep;120(9):3099-102. doi: 10.1172/JCI44312. Epub 2010 Aug 25.

47.

The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.

Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA.

J Immunol. 2010 May 15;184(10):5755-67. doi: 10.4049/jimmunol.0901638. Epub 2010 Apr 19.

48.

Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Fabrizio K, Manix C, Guimaraes AJ, Nosanchuk JD, Pirofski LA.

Clin Vaccine Immunol. 2010 May;17(5):713-21. doi: 10.1128/CVI.00410-09. Epub 2010 Mar 3.

49.

Commentary: IDSA guidelines for improving the teaching of preclinical medical microbiology and infectious diseases.

Southwick F, Katona P, Kauffman C, Monroe S, Pirofski LA, del Rio C, Gallis H, Dismukes W; Infectious Diseases Society of America Preclinical Curriculum Committee.

Acad Med. 2010 Jan;85(1):19-22. doi: 10.1097/ACM.0b013e3181c485c5.

PMID:
20042815
50.

Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Subramaniam KS, Datta K, Marks MS, Pirofski LA.

Infect Immun. 2010 Jan;78(1):441-52. doi: 10.1128/IAI.00506-09. Epub 2009 Nov 9.

Supplemental Content

Loading ...
Support Center